Prevalence and risk factors of postpartum depressive symptoms at 42 days among 2462 women in China.

Prevalence and risk factors of postpartum depressive symptoms at 42 days among 2462 women in China.

Publication date: Jan 18, 2024

Postpartum depression is a common and serious mental health problem that is affecting an increasing percentage of the world’s population. We aimed to evaluate the prevalence of postpartum depressive symptoms in Beijing, China, during the COVID-19 pandemic and identify several potential risk factors. This was a cross-sectional observational study conducted at Peking University First Hospital from 2020 to 2021. Women who delivered and had postpartum reviews at 42 days after delivery were invited to complete the Chinese version of the Edinburgh Postnatal Depression Scale (EPDS) under the guidance of trained nurses. A score of ≥10 was used as the threshold of postpartum depression. t-tests, chi-square tests or Mann-Whitney U tests were applied. A multivariate logistic regression analysis was conducted to assess the risk factors for postpartum depressive symptoms. A total of 2462 mothers were included in this study, 20. 2 % of whom were considered to have postpartum depressive symptoms. Multivariate logistic regression analysis showed that formula feeding (OR = 2. 219, 95 % CI: 1. 300-3. 786, P = 0. 013), preterm birth (OR = 1. 619, 95 % CI: 1. 108-2. 367, P = 0. 013), cervical insufficiency (OR 3. 022, 95 % CI: 1. 200-7. 615, P = 0. 019) and history of depression (OR = 6. 519, 95 % CI: 1. 537-27. 659, P = 0. 011) were associated with a high prevalence of postpartum depressive symptoms. There is a high prevalence of postpartum depressive symptoms in developed regions of China during the COVID-19 pandemic. More attention should be given to mothers with risk factors for PPD, and follow-up care is needed.

Concepts Keywords
42days China
China COVID-19
Nurses Postpartum depression
Pandemic Prevalence
Postnatal Risk factors

Semantics

Type Source Name
disease MESH Postpartum depression
disease VO population
disease MESH COVID-19 pandemic
disease MESH preterm birth
disease IDO history
drug DRUGBANK p-Phenylenediamine

Original Article

(Visited 2 times, 1 visits today)